2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Study Population, Human, Adult, Animal Model
PAPER

4094 Genetic predictors of cardiovascular disease (CVD) following hematopoietic stem cell transplantation (HSCT)

Neha Deshpande, PhD, Wei Sha, PhD2, Simeon Owuor3, Julie Call4, Carl Langefeld, PhD5, Rupali Bose, MS,MBA6, Sarah Morris, PharmD7, Grace Nguyen, PharmD8, Lawrence J Druhan, PhD9, Jing Ai, MD, PhD10, Thomas G Knight, MD11, Brittany Knick Ragon, MD12, Aleksander Chojecki, MD13, Nilay Shah, MD14, Srinivasa Reddy Sanikommu, MD15, Yifan Pang, MD16, Manisha Bhutani, MD17, Michael R. Grunwald, MD18, Jai Patel, PharmD19
1 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
2 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
3 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
4 Wake Forest University Baptist Medical Center, Winston Salem, North Carolina, United States
5 Wake Forest University Baptist Medical Center, Winston Salem, North Carolina, United States
6 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
7 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
8 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
9 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
10 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
11 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
12 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
13 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
14 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
15 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
16 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
17 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
18 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States
19 Atrium Health Levine Cancer Institute (Pharmacology/Hematology/Biostatistics), Charlotte, North Carolina, United States

Background: Studies have shown increased short and long-term CVD risk among patients and survivors of myeloma, leukemia, and other hematologic malignancies. One analysis found similar short-term (≤100 days) CVD incidence across HSCT types, but higher long-term CVD incidence among allogeneic recipients compared to autologous recipients. We previously showed that 16% of post-transplant cyclophosphamide (PTCy) treated patients experienced CVD within 30 days after allogeneic HSCT. CVD risk may be driven by clinical factors, genetic factors, and the cardiotoxic effects of anticancer therapies. We aim to identify genetic markers of CVD in adult autologous and allogeneic HSCT recipients.

Methods: This is a retrospective genomic study of HSCT patients at Atrium Health Levine Cancer Institute between January 2014 and July 2024. Germline DNA was extracted from buccal swabs, and genotyping was performed using the Illumina Global Diversity Array with Enhanced PGx. The analysis focused on 310 single nucleotide polymorphisms (SNPs) in 22 genes. CVD risk genes designated by the American College of Medical Genetics and Genomics (ACMG) and available on the GDA were selected:ACTA2/FAS, APOB, CTNNA3, KCNH2, KCNQ1, PCSK9, RYR1, TGFBR2, TRDN. Since PTCy was used in allogeneic HSCT recipients, genes involved in Cy metabolism were also included: ALDH1A1, ALDH3A1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTM1, GSTP1, GSTT1. The primary endpoint was time from HSCT to CVD occurrence, including acute or chronic ischemic heart disease, acute myocardial infarction, angina pectoris, atrial fibrillation or flutter, other arrhythmias, cardiomyopathy, heart failure, hypertensive heart disease, pericardial effusion, pericarditis, peripheral vascular disease, and pulmonary edema. Covariates included age, sex, ancestral variation, diabetes, dyslipidemia, hypertension, atherosclerosis, and CVDs within 2 years prior to HSCT. A Cox proportional hazards model was generated to evaluate the association between each SNP and time to CVD, adjusting for covariates.  A PCA-based Bonferroni correction accounting for linkage disequilibrium among candidate SNPs was applied, with p<0.05 considered statistically significant.

Results: Of 277 HSCT recipients, median age was 61 (range 22-80), 61% were male, 74% White, and 21% Black.  Among 129 allogeneic transplant recipients, 55% received haploidentical, 26% received matched related, and 19% received matched unrelated donor HSCT. The cumulative incidence of CVD at 90 days, 180 days, and 5 years was 26%, 29%, and 57% among allogeneic HSCT recipients, compared to 20%, 27%, and 53%, respectively, among autologous HSCT recipients. After exclusion of samples with poor DNA quality or quantity and those that failed genotyping quality control, the following SNPs were significantly associated with time to CVD among 217 patients (92 allogeneic and 125 autologous HSCT recipients): CYP2A6 rs1137115 (HR 1.6, 95% CI 1.1-2.3, p=0.0095), ACTA2/FAS rs2234767 (HR 1.6, 95% CI 1-2.6, p=0.025), GSTP1 rs1695 (HR 0.7, 95% CI 0.5-0.9, p=0.045), and TRDN rs4897302 (HR 0.7, 95% CI 0.5-0.9, p=0.039). GSTT1 rs1007888 demonstrated a differential association with CVD according to transplant type (p=0.0197), with the strongest association observed among allogeneic recipients. Consistent with these findings, analysis of the allogeneic subgroup showed that CYP2A6 rs1137115 (HR 2.4, 95% CI 1.3-4.4, p=0.0034) and GSTT1 rs1007888 (HR 1.8, 95% CI 1.2-2.8, p=0.0081) remained significantly associated with time to CVD, supporting a potential role for Cy related pharmacogenetic effects.

Conclusion: Cardiotoxicity following HSCT was common in both allogeneic and autologous recipients. Variants in CYP2A6, ACTA2/FAS and GSTT1 were associated with increased risk of CVD, whereas variants in GSTP1 and TRDN were associated with decreased risk of CVD. In allogeneic recipients, association between CVD risk and SNPs in CYP2A6 and GSTT1 imply a role for PTCy-related cardiotoxicity. These findings suggest that SNPs may influence cardiotoxicity through pathways involved in drug metabolism (CYP2A6, GSTT1), oxidative stress responses (GSTP1, GSTT1), apoptotic signaling (ACTA2/FAS), and cardiac calcium regulation (TRDN). These findings require replication but support the potential role of genetic markers in post-HSCT CVD risk stratification to improve identification of high-risk patients and guide earlier clinical intervention.

 

Neha Deshpande, PhD: No relevant conflicts of interest to declare.